| scholarly article | Q13442814 |
| P50 | author | Gabriel Nussbaum | Q88438546 |
| P2093 | author name string | Michael Elkin | |
| Tamar Peretz | |||
| Amichay Meirovitz | |||
| Limor Appelbaum | |||
| Karen Meir | |||
| Esther Hermano | |||
| P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
| Pancreatic adenocarcinoma upregulated factor promotes metastasis by regulating TLR/CXCR4 activation | Q24298015 | ||
| Neutralizing tumor-promoting chronic inflammation: a magic bullet? | Q26830931 | ||
| Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling | Q27002391 | ||
| The pancreas cancer microenvironment | Q27026705 | ||
| Cancer-related inflammation | Q27860907 | ||
| Heparanase expression in primary and metastatic pancreatic cancer | Q28201783 | ||
| Markers of mouse macrophage development detected by monoclonal antibodies | Q28247978 | ||
| Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2 | Q28273441 | ||
| Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis | Q28305755 | ||
| Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases | Q28475274 | ||
| Macrophage diversity enhances tumor progression and metastasis | Q29615847 | ||
| Versatile role of heparanase in inflammation | Q33770777 | ||
| TLR4 dependent heparan sulphate-induced pancreatic inflammatory response is IRF3-mediated | Q34107852 | ||
| Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation | Q34250138 | ||
| Inflammation and the development of pancreatic cancer | Q34646491 | ||
| Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. | Q34786695 | ||
| Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice | Q34876266 | ||
| Increased IL-10 mRNA expression in tumor-associated macrophage correlated with late stage of lung cancer | Q35052823 | ||
| Macrophage infiltration predicts a poor prognosis for human ewing sarcoma | Q35168030 | ||
| Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma | Q35369888 | ||
| Distinct modes of macrophage recognition for apoptotic and necrotic cells are not specified exclusively by phosphatidylserine exposure | Q35582768 | ||
| Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model | Q35954142 | ||
| MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. | Q36193536 | ||
| High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer | Q36510093 | ||
| Oncogenic transcription factors: cornerstones of inflammation-linked pancreatic carcinogenesis | Q36516948 | ||
| Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses | Q36586333 | ||
| Activation of TLR4 is required for the synergistic induction of dual oxidase 2 and dual oxidase A2 by IFN-γ and lipopolysaccharide in human pancreatic cancer cell lines | Q36586351 | ||
| Heparanase expression is a prognostic indicator for postoperative survival in pancreatic adenocarcinoma | Q36644302 | ||
| Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer | Q36663615 | ||
| Proteoglycans in cancer biology, tumour microenvironment and angiogenesis | Q36787608 | ||
| The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. | Q37045970 | ||
| Targeting the tumor microenvironment: from understanding pathways to effective clinical trials | Q37274132 | ||
| Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation | Q37594369 | ||
| Epidemiology of pancreatic cancer: an overview | Q37608905 | ||
| Mechanisms of tumor cell necrosis. | Q37705538 | ||
| Endogenous toll-like receptor ligands and their biological significance | Q37772578 | ||
| Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. | Q37788815 | ||
| Exogenous or endogenous Toll-like receptor ligands: which is the MVP in tumorigenesis? | Q37952071 | ||
| The heparanase/syndecan-1 axis in cancer: mechanisms and therapies | Q38078480 | ||
| The stromal compartments in pancreatic cancer: are there any therapeutic targets? | Q38154098 | ||
| Downregulation of heparanase by RNA interference inhibits invasion and tumorigenesis of hepatocellular cancer cells in vitro and in vivo | Q39408085 | ||
| Downregulating the expression of heparanase inhibits the invasion, angiogenesis and metastasis of human hepatocellular carcinoma | Q40139495 | ||
| Conditional signaling by Toll-like receptor 4. | Q40452634 | ||
| Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. | Q40733888 | ||
| High expression of heparanase is significantly associated with dedifferentiation and lymph node metastasis in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA and via HIF1a to HB-EGF and bFGF. | Q43487753 | ||
| Elevated serum heparanase-1 levels in patients with pancreatic carcinoma are associated with poor survival | Q46875711 | ||
| Analysis of gene expression in the tumor-associated macrophage. | Q50968644 | ||
| Heparanase promotes lymphangiogenesis and tumor invasion in pancreatic neuroendocrine tumors. | Q51019130 | ||
| Heparanase expression by Barrett's epithelium and during esophageal carcinoma progression. | Q53371446 | ||
| Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer | Q60594558 | ||
| The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma | Q73877559 | ||
| Heparanase as mediator of angiogenesis: mode of action | Q74101720 | ||
| High heparanase activity in multiple myeloma is associated with elevated microvessel density | Q75207710 | ||
| Heparanase upregulation by colonic epithelium in inflammatory bowel disease | Q79241944 | ||
| Heparanase expression correlates with malignant potential in human colon cancer | Q81213784 | ||
| Dynamics of the immune reaction to pancreatic cancer from inception to invasion | Q81381605 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | macrophage | Q184204 |
| pancreatic carcinoma | Q18556536 | ||
| P577 | publication date | 2014-10-18 | |
| P1433 | published in | Journal of the National Cancer Institute | Q400279 |
| P1476 | title | Macrophage polarization in pancreatic carcinoma: role of heparanase enzyme | |
| P478 | volume | 106 |
| Q52659459 | A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours. |
| Q36319886 | BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages. |
| Q33876637 | Chemotherapy and tumor microenvironment of pancreatic cancer. |
| Q64089855 | Computer-aided assessment of the extra-cellular matrix during pancreatic carcinogenesis: a pilot study |
| Q91798106 | Forty Years of Basic and Translational Heparanase Research |
| Q37372466 | Genetic variations associated with gemcitabine treatment outcome in pancreatic cancer. |
| Q26765438 | Genetics and biology of pancreatic ductal adenocarcinoma |
| Q36964047 | HMGB1 exacerbates bronchiolitis obliterans syndrome via RAGE/NF-κB/HPSE signaling to enhance latent TGF-β release from ECM. |
| Q58585910 | Heparan Sulfate Mimetics in Cancer Therapy: The Challenge to Define Structural Determinants and the Relevance of Targets for Optimal Activity |
| Q41118533 | Heparanase and cancer progression: New directions, new promises |
| Q37746011 | Heparanase augments insulin receptor signaling in breast carcinoma |
| Q37473740 | Heparanase is required for activation and function of macrophages. |
| Q38985052 | Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy |
| Q42587945 | Heparanase: From basic research to therapeutic applications in cancer and inflammation |
| Q55414494 | Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors. |
| Q64081265 | Leukocyte Heparanase: A Double-Edged Sword in Tumor Progression |
| Q47377873 | Opposing Functions of Heparanase-1 and Heparanase-2 in Cancer Progression |
| Q35836200 | Recent data concerning heparanase: focus on fibrosis, inflammation and cancer |
| Q92541928 | Regulation of Heparanase in Diabetes-Associated Pancreatic Carcinoma |
| Q64100384 | TAMing pancreatic cancer: combat with a double edged sword |
| Q28076103 | Targeting tumor-associated macrophages to combat pancreatic cancer |
| Q89965719 | The Heparan Sulfate Mimetic PG545 Modulates T Cell Responses and Prevents Delayed-Type Hypersensitivity |
| Q33904342 | The Presence of Interleukin-13 at Pancreatic ADM/PanIN Lesions Alters Macrophage Populations and Mediates Pancreatic Tumorigenesis |
| Q42004230 | The Role of Heparanase in the Pathogenesis of Acute Pancreatitis: A Potential Therapeutic Target |
| Q39080564 | The advancements of heparanase in fibrosis |
| Q92058056 | The relationship between pancreatic cancer and hypercoagulability: a comprehensive review on epidemiological and biological issues |
| Q38564735 | Tumor-associated macrophages in cancers |
| Q35674290 | Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms |
Search more.